@article{e1d2bcd270e240778d4595be832c7bef,
title = "A blueprint for cancer screening and early detection: Advancing screening{\textquoteright}s contribution to cancer control",
abstract = "From the mid-20th century, accumulating evidence has supported the introduction of screening for cancers of the cervix, breast, colon and rectum, prostate (via shared decisions), and lung. The opportunity to detect and treat precursor lesions and invasive disease at a more favorable stage has contributed substantially to reduced incidence, morbidity, and mortality. However, as new discoveries portend advancements in technology and risk-based screening, we fail to fulfill the greatest potential of the existing technology, in terms of both full access among the target population and the delivery of state-of-the art care at each crucial step in the cascade of events that characterize successful cancer screening. There also is insufficient commitment to invest in the development of new technologies, incentivize the development of new ideas, and rapidly evaluate promising new technology. In this report, the authors summarize the status of cancer screening and propose a blueprint for the nation to further advance the contribution of screening to cancer control.",
keywords = "breast neoplasms, cervical neoplasms, colorectal neoplasms, lung neoplasms, mass screening, prostate neoplasms",
author = "Wender, {Richard C.} and Brawley, {Otis W.} and Fedewa, {Stacey A.} and Ted Gansler and Smith, {Robert A.}",
note = "Funding Information: C. Wender, MD, American Cancer Society, 250 Williams St, Suite 600, Atlanta, GA 30303; richard.wender@ cancer.org doi: 10.3322/caac.21550. Available online at cacancerjournal.com DISCLOSURES: The American Cancer Society (ACS) receives partial funding from the Centers for Disease Control and Prevention to support the National Colorectal Cancer Roundtable, of which Richard C. Wender is the Chair and Robert A. Smith is the Co-Chair, to support initiatives related to colorectal cancer screening. The ACS also received contributions from Bracco Diagnostics Inc, Polymedco Inc, Exact Sciences, Medtronic GI Solutions Inc, Quest Diagnostics, Epigenomics Inc, Clinical Genomics, Medial EarlySign, The American Society for Gastrointestinal Endoscopy, The American College of Gastroenterology, The Center for Colon Cancer Research, The Colon Cancer Coalition, The Colorectal Cancer Alliance, Fight Colorectal Cancer, Old Dominion Society of Gastroenterology Nurses and Associates, and The American Gastroenterological Association to support the annual meeting of the National Colorectal Cancer Roundtable. The ACS receives funding from AstraZeneca Inc to provide partial support for the National Lung Cancer Roundtable, of which Robert A. Smith is the principal investigator (but receives no salary support), to promote initiatives focused on public and provider education, shared decision making, screening, tobacco treatment, and guideline-adherent diagnosis and therapy. ACS cancer screening guideline development is supported by ACS operational funds; neither the Roundtables nor sources of funding described in this disclosure have had any role, involvement, or made any financial contribution to ACS screening guideline development or approval. Otis Funding Information: W. Brawley and Stacey A. Fedewa are employed by the ACS, which received a grant from Merck Inc for intramural research outside the submitted work; however, their salary is solely funded through the ACS. Ted Gansler reports no potential conflicts of interest. Publisher Copyright: {\textcopyright} 2019 American Cancer Society",
year = "2019",
month = jan,
day = "1",
doi = "10.3322/caac.21550",
language = "English (US)",
volume = "69",
pages = "50--79",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "1",
}